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Article focus
  oxidative stress is associated with bone loss.
  We assessed in vitro the putative antioxidant 
properties of the osteogenic parathyroid 
hormone-related protein (PTHrP) and their 
ability to modulate osteoblastic function.
Key messages
  PTHrP displays antioxidative stress activity 
in mouse and human osteoblastic cells.
  PTHrP (1-37) and PTHrP (107-111) (osteo-
statin) counteract the decrease of osteo-
blastic function triggered by oxidative stress.
  N- and C-terminal domains of PTHrP 
exhibit similar antioxidative stress  features 
through different signalling mechanisms 
in osteoblastic cells.
Strengths and limitations
  PTHrP preserves osteoblastic function in 
an in vitro oxidative environment that 
 further supports the putative use of PTHrP 
peptides as osteoporosis therapy.
  Caution should be taken when translat-
ing these in vitro results to an in vivo 
scenario.
parathyroid hormone-related  
protein exhibits antioxidant features  
in osteoblastic cells through its 
n-terminal and osteostatin domains
Objectives
oxidative stress plays a major role in the onset and progression of involutional osteoporosis. 
However, classical antioxidants fail to restore osteoblast function. Interestingly, the bone 
anabolism of parathyroid hormone (pTH) has been shown to be associated with its ability to 
counteract oxidative stress in osteoblasts. The pTH counterpart in bone, which is the pTH-
related protein (pTHrp), displays osteogenic actions through both its n-terminal pTH-like 
region and the c-terminal domain.
Methods
We examined and compared the antioxidant capacity of pTHrp (1-37) with the c-terminal 
pTHrp domain comprising the 107-111 epitope (osteostatin) in both murine osteoblastic 
Mc3T3-e1 cells and primary human osteoblastic cells.
Results
We showed that both n- and c-terminal pTHrp peptides at 100 nM decreased reactive oxy-
gen species production and forkhead box protein o activation following hydrogen perox-
ide (H2o2)-induced oxidation, which was related to decreased lipid oxidative damage and 
 caspase-3 activation in these cells. This was associated with their ability to restore the delete-
rious effects of H2o2 on cell growth and alkaline phosphatase activity, as well as on the expres-
sion of various osteoblast differentiation genes. The addition of Rp-cyclic 3′,5′- hydrogen 
phosphorothioate adenosine triethylammonium salt (a cyclic 3',5'-adenosine monophos-
phate antagonist) and calphostin c (a protein kinase c inhibitor), or a pTH type 1 receptor 
antagonist, abrogated the effects of n-terminal pTHrp, whereas protein phosphatase 1 (an 
src kinase activity inhibitor), sU1498 (a vascular endothelial growth factor receptor 2 inhibi-
tor), or an anti osteostatin antiserum, inhibited the effects of c-terminal pTHrp.
Conclusion
These findings indicate that the antioxidant properties of pTHrp act through its n- and 
c- terminal domains and provide novel insights into the osteogenic action of pTHrp.
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introduction
It is widely accepted that bone mass in humans starts to 
decline between the second and third decades of life, and 
this has been attributed to an increase in oxidative stress.1,2 
Compelling evidence indicates that oxidative stress is a 
major cause of the ageing process, and that it occurs as the 
result of an imbalance between the production of reactive 
oxygen species (roS) and the molecular defence mecha-
nisms that control roS, such as antioxidant enzymes 
 catalase (CaT), superoxide dismutase (SoD), glutathione 
peroxidase (GPx), and antioxidant compounds  (glutathione, 
among others).3,4 It has been reported that age-related 
conditions that are associated with bone derangement, 
such as post-menopausal oestrogen depletion and diabe-
tes mellitus, produce an increase of roS.5,6 The expression 
of roS inhibiting molecules, namely the enzymes SoD7 
and CaT,8 as well as factors that induce cell cycle arrest in 
response to excessive oxidative stress (such as growth 
arrest DNa damage 45 protein),9 can be regulated by fork-
head box protein o (FoXo) transcription factors, which 
are essential to bone integrity.10 In fact, it has recently been 
demonstrated that knocking down SoD results in bone 
deterioration in mice.11 In humans, an augmented oxida-
tive stress has been traced to decreased bone mineral den-
sity.12,13 The mechanisms by which oxidative stress may 
impair bone formation are complex and involve DNa dam-
age,14 lipid peroxidation,15 protein carbonylation,16 inhibi-
tion of Wnt pathway activation,17 decreased osteoblast 
proliferation18 and differentiation,19,20 and increased osteo-
blast apoptosis.21
Parathyroid hormone (PTH)-related protein (PTHrP) is 
abundantly expressed in bone, where it performs an impor-
tant role in bone formation and remodelling; similarly to 
PTH, intermittent administration of PTHrP displays anabolic 
actions in rodents and/or humans.22 In fact, the N-terminal 
region of PTHrP shows homology with the same region of 
PTH and interacts with the common PTH type 1 receptor 
(PTH1r), which is a class II G protein- coupled receptor. PTH 
binding to PTH1r produces the activation of protein kinase a 
(PKa) by cyclic 3',5'- adenosine monophosphate (caMP) 
and phospholipase C.23 on the other hand, the PTH-
unrelated C-terminal tail of PTHrP contains the 107-111 
epitope (named osteostatin), which does not interact with 
the parathyroid hormone 1 receptor (PTHr1) but can 
apparently signal through opening voltage- sensitive cal-
cium channels and protein kinase C (PKC) activation in 
osteoblastic cells.24 It has recently been shown that osteo-
statin may transactivate vascular endothelial growth factor 
receptor 2 (vEGFr2) to promote osteoblastic function 
through an Src kinase- mediated mechanism.25
recent data have disclosed the impact of the antioxida-
tive stress properties of PTH on its bone anabolic action in 
aged mice.26 In this regard, we recently reported that 
PTHrP (1-36) and PTHrP (107-139) were able to prevent 
the inhibitory effect of oxidative stress on the Wnt pathway 
activation in mouse mesenchymal C3H10T1/2 cells, 
suggesting their antioxidant potential.27 The aim of the 
present study was to determine the antioxidant properties 
of both N- and C-terminal domains of PTHrP in murine 
osteoblastic MC3T3-E1 cells and human osteoblastic cells 
(hoBs). regarding the latter domain, we tested both the 
native fragment PTHrP (107-139) and osteostatin, both of 
which have a simple structure that would make them 
attractive agents for promoting bone formation and bone 
regeneration.28-32 The impact of the antioxidant properties 
of these PTHrP peptides on their ability to affect murine 
and hoB function has also been explored in this study.
Materials and Methods
Cells and reagents. Previously well-characterized osteo-
blastic MC3T3-E1-subclon 4 cells (Crl-2593; american 
Type Culture Collection, Manassas, virginia), showing 
high mineralization capacity under differentiation condi-
tions, were used. These cells have been used in previous 
studies evaluating several osteogenic actions of PTH and 
PTHrP.28,29,33,34 Primary hoBs were obtained from tra-
becular bone explants from two osteoarthritic patients 
undergoing total knee arthroplasty surgery, as previously 
reported.22,28,29,35-37 Briefly, hoBs were cultured from bone 
slices with Dulbecco’s modified Eagle medium (MEM; 
Thermo Fisher Scientific, Waltham, Massachusetts) con-
taining 20% heat-inactivated fetal bovine serum (FBS), 
2 mM glutamine and 100 u/ml of penicillin/streptomy-
cin, and experiments were carried out using cells at the 
third passage. The Ethics Committee for Clinical research 
at Instituto de Investigación Sanitaria-Fundación Jiménéz 
Díaz, Madrid, Spain approved the protocol, and written 
informed consent from the patients was granted.
MC3T3-E1 cells were grown in α-MEM with 10% FBS 
and antibiotics were made up of 1% penicillin/streptomy-
cin (standard medium) in a humidified atmosphere of 5% 
Co2 at 37°C. When present, PTH (1-34) (Sigma-aldrich, St 
louis, Missouri), PTHrP (1-37), PTHrP (107-139), and osteo-
statin (Bachem aG, Bubendorf, Switzerland), depending 
on the type of experiment (detailed in each case), were 
added at 100 nM to the cell culture. This dose has demon-
strated osteogenic capacity in previous studies using 
PTHrP (1-37) and osteostatin.27,29,34,38 In order to evaluate 
gene expression changes as described below, the PTH1r 
antagonist (asn10, leu11, D-Trp12) PTHrP (7-34) amide 
(PTHrP 7-34), at 100 nM, or neutralizing rabbit polyclonal 
antiserum C7 recognizing the osteostatin epitope in the 
entire PTHrP molecule, at 1:100 dilution,39 were added 
together with PTHrP (1-37) or osteostatin, respectively. 
CaT (Sigma-aldrich), at 200 u/ml, was used as an anti-
oxidant control. In alkaline phosphatase (alP) activity 
and viability assays, we used the PKa inhibitor, adeno-
sine 3’,5’-cyclic monophosphorothioate, and rp-isomer 
(rp-cyclic 3’,5’-hydrogen phosphorothioate adenosine 
tri ethylammonium salt (rp-caMPs)) (Santa Cruz Bio-
technology Inc., Santa Cruz, California), at 25 µM; the PKC 
inhibitor, calphostin C (CalpC) (Calbiochem Corp., la 
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Jolla, California), at 250 nM; or the Src kinase inhibitor 
PP-1 (Calbiochem Corp.) and vEGFr2 phosphorylation 
inhibitor Su1498 (Sigma-aldrich), each at 10 µM, all of 
them added 30 minutes prior to the tested peptides.
ROS level determination. roS were measured by evaluat-
ing the fluorescence increment of 2’,7’- dichlorofluorescein 
diacetate (DCF) dye reacting with strong oxidants such as 
cell peroxides, as previously described.40,41 Briefly, a final 
concentration of 10 µM DCF was added to subconfluent 
cells (10 000 cells/cm2 to 20 000 cells/cm2) in a FBS-
depleted medium for 15 minutes at 37ºC. after extensive 
washing with phosphate-buffered saline (PBS), pH 7.4, 
cells were incubated for another 15 minutes, followed by 
treatment with the tested peptides at 100 nM for ten min-
utes in standard medium. after removing this medium, 
cells were washed with PBS followed by an addition of 
200 µM hydrogen peroxide (H2o2) for ten minutes in a 
FBS-depleted medium and then tripsinized, measuring 
the increment of fluorescence in a FaCSCalibur flow 
cytometer (BD Biosciences, Franklin lakes, New Jersey).
Confocal experiments were also performed following 
the same protocol described above for DCF loading and 
peptide and H2o2 treatments. Cells were subsequently 
fixed with methanol including the DNa fluorescent dye 
4’,6-diamidino-2-phenylindole dihydrochloride (1 mg/ml) 
for ten minutes, mounted in FluorSave reagent (Cal-
biochem Corp.) and examined using a leica DM IrB 
confocal microscope (leica, Wetzlar, Germany).
FOXO-luciferase (luc) assay. Subconfluent MC3T3-E1 
cells were transfected with a mixture of 1 µg of FoXo-
luc reporter plasmid and 5 ng of a renilla coding plas-
mid (Promega Corp., Fitchburg, Wisconsin) (transfection 
control) using X-tremeGENE 9 DNa Transfection reagent 
(roche Diagnostics, Indianapolis, Indiana), following 
the manufacturer’s instructions. after transfection, cells 
were treated with the peptides (each at 100 nM) for one 
hour in standard medium and then washed with PBS 
before the addition of 100 µM H2o2, followed by an over-
night incubation in 1% FBS-containing medium at 37ºC. 
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Fig. 1e Fig. 1fFig. 1d
Fig. 1b Fig. 1cFig. 1a
oxidative stress induced by hydrogen peroxide (H2o2) can be prevented by N- and C-terminal parathyroid hormone (PTH) and PTH-related protein (PTHrP) pep-
tides in osteoblastic cells. Cells were exposed to 200 μM H2o2 following pretreatment with each PTHrP peptide or PTH (1-34) (100 nM) or control. reactive oxygen 
species levels were measured by 2’,7’dichloro fluorescein diacetate (DFC) fluorescence. representative flow cytometry images for a) control, b) H2o2, c) PTH + 
H2o2, d) PTHrP (1-37) + H2o2, e) PTHrP (107-139) + H2o2, and f) osteostatin + H2o2. M1 and M2 denote the two areas used to quantify increment in fluorescence.
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Fig. 2
representative flow cytometry quantification. †p < 0.01 versus control; 
‡p < 0.05 versus H2o2 treatment; §p < 0.01 versus H2o2 treatment. Data are 
represented by mean ± standard error of the mean (sem). Kruskal–Wallis test 
followed by Dunn’s post hoc test. N-ter(1-37), C-ter(107-139), and ost denote 
parathyroid hormone-related protein (1-37), parathyroid hormone-related 
protein (107-139), and osteostatin, respectively.
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Thereafter, cells were homogenized with a lysis buffer, 
and luciferase and renilla activities were quantified with a 
dual luciferase kit (Promega Corp.), following the manu-
facturer’s instructions, using the FB12 tube luminometer 
(Berthold Technologies GmbH & Co. KG, Bad Wildbad, 
Germany). renilla activity values were used to normalize 
the luciferase values.
Malondialdehyde (MDA) assay. lipid peroxidation levels 
were determined by measuring the formation of MDa 
using a commercial kit (Biovision, Inc., Mountain view, 
California) per the manufacturer’s instructions. Briefly, 
MC3T3-E1 cells and hoBs (2 × 106 cells) were pretreated 
with PTHrP (1-37), PTHrP (107-139), osteostatin or PTH 
(1-34), each at 100 nM, for ten minutes in a serum-
depleted medium. Cells were then washed three times 
with PBS and treated with 200 µM H2o2 for 24 hours, fol-
lowed by centrifugation at 500 ×g for five minutes. The 
pellets were then washed three times with PBS. Pellets 
were subsequently resuspended in 300 μl of lysis buffer, 
as supplied by the kit, with 3 μl butylated hydroxytoluene 
(0.1 mM), sonicated, and centrifuged (13 000 ×g for ten 
minutes). The supernatants (200 μl) from each sample 
were added to 600 μl of thiobarbituric acid and incubated 
in a water bath at 95°C for 60 minutes. Samples were then 
ice-cooled for ten minutes and 200 μl (from each 800 μl of 
reaction mixture) was placed into a 96-well microplate 
for measuring absorbance at 532 nm. The MDa supplied 
in the kit was used as standard and MDa levels were 
determined by comparing the absorbance of samples 
with that of the standard controls. The protein concen-
tration of the samples was measured with bicinchoninic 
acid protein assay (Sigma-aldrich), using bovine serum 
albumin as standard. results were expressed as nmols of 
MDa per mg of protein.
Caspase-3 assay. Subconfluent cells were serum-depleted 
overnight prior to incubation with the different peptides 
tested (each at 100 nM) for one hour in FBS-depleted 
medium. after washing the cells with PBS, 100 µM H2o2 
was added for two, six, and 24 hours in the latter medium. 
Caspase-3 activity was analyzed using the CaspaCE assay 
System (Promega) following the manufacturer’s instruc-
tions. In brief, cell extracts obtained in lysis buffer were 
submitted to three freeze-and-thaw cycles and then 
centrifuged at 15 000 g at 4ºC. Supernatants were then 
incubated with the substrate ac-DEvD-p-nitroaniline 
(Sigma-aldrich) for four hours at 37ºC, and caspase-3 activ-
ity was determined by measuring absorbance at 405 nm. 
Caspase activity was expressed as pmol p-nitroaniline/h/µg 
protein (measured as described above).
Cell proliferation. Cells were seeded at 3000 cells/cm2 
in 96-well plates. after 24 hours, cells were treated with 
each tested peptide, at 100 nM, or CaT (an antioxidant 
control) at 200 u/ml, for one hour in standard medium. 
after washing with PBS, 200 µM H2o2 was added for one 
hour in FBS-depleted medium. The medium was then 
replaced with the standard medium. This procedure was 
repeated after 48 hours and 24 hours after this repeti-
tion we proceeded to measure cell proliferation (a total 
five days since assay onset). at this time, cell prolifera-
tion was determined by the addition of resazurin salt 
solution42 (Sigma-aldrich), at 10 µg/ml. after four hours, 
absorbance was measured at both 540 nm and 630 nm. 
 Fig. 3d Fig. 3e Fig. 3f
Confocal microscopy images of MC3T3-E1 cells for a) control, b) H2o2, c) parathyroid hormone (PTH) + H2o2, d) PTH-related protein (1-37) + H2o2, e) PTH-
related protein (107-139) + H2o2, and f) osteostatin + H2o. The white bar denotes 75 μm.
 Fig. 3a Fig. 3b Fig. 3c
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The percentage difference in cell growth between treated 
and control cells was calculated using the following 
equation: [(o2 × a1) - (o1 × a2) / (o2 × P1) - (o1 × P2)] 
× 100, where o1 and o2 are the molar extinction coef-
ficients of oxidized resazurin salt at 540 nm and 630 nm, 
respectively; a1 and a2 are the absorbance of treated 
cells at 540 nm and 630 nm, respectively; and P1 and P2 
correspond to the absorbance of control cells (cells with-
out treatment) at 540 nm and 630 nm, respectively.
Cell viability. Subclonfluent MC3T3-E1 cells were pre-
treated for 30 minutes with the inhibitors prior to the 
addition of PTHrP peptides for 30 minutes in standard 
medium. Controls were not pretreated. The cells were 
then washed with PBS and incubated with 200 µM H2o2 
for six hours in either serum-depleted or standard medium 
(to control for endogenous growth factors in FBS). after 
treatment, nonadherent cells were collected and pooled 
with adherent cells (following trypsinization), and cell via-
bility was assessed by trypan blue exclusion, as previously 
described.36,43 Nonviable cells exhibiting intracellular try-
pan blue staining and total cell numbers were counted to 
calculate the percentage of cell viability in each case.
AlP activity assay. Subconfluent MC3T3-E1 cells and hoBs 
were preincubated with the different inhibitors for 30 min-
utes, subsequently followed by the addition of the tested 
PTHrP peptides, each at 100 nM for one hour in standard 
medium and 200 µM of H2o2 for two hours in FBS-depleted 
medium. The FBS-depleted medium was then replaced 
with standard medium and cells were incubated for a fur-
ther 24 hours. alP activity was measured in cell extracts 
obtained with PBS and 0.1% Triton X-100 (Sigma-aldrich) 
using p-nitrophenyl phosphate as substrate, as previously 
described.28 alP activity was normalized to cell protein con-
tent determined as described in MDa and Caspase assays.
Quantitative real-time polymerase chain reaction (PCR). 
Subconfluent MC3T3-E1 cells were treated as described 
for the alP activity assay. Following treatment, cell total 
rNa was extracted with TrIzol (Thermo Fisher Scientific, 
 Fig. 4d Fig. 4e Fig. 4f
Confocal microscopy images of human osteoblastic cells for a) control, b) H2o2, c) parathyroid hormone (PTH) + H2o2, d) PTH-related protein (1-37) + H2o2, 
e) PTH-related protein (107-139) + H2o2, and f) osteostatin + H2o. The white bar denotes 20 μm.
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Fig. 5
Forkhead box protein o (FoXo) activity in MC3T3-E1 cells was measured 
with a FoXo-luciferase plasmid. Bars represent the mean ± standard error 
of the mean (sem) of three independent experiments performed in triplicate. 
†p < 0.01 versus control; §p < 0.01 versus H2o2 treatment. Kruskal–Wallis test 
followed by Dunn’s post hoc test. N-ter(1-37), C-ter(107-139), and ost denote 
parathyroid hormone-related protein (1-37), parathyroid hormone-related 
protein (107-139), and osteostatin, respectively.
 Fig. 4a Fig. 4b Fig. 4c
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Waltham, Massachusetts). Synthesis of complementary 
DNa (cDNa) was performed using the high-capacity 
cDNa reverse transcription kit following the manufactur-
er’s instructions (applied Biosystems, Grand Island, New 
york). a quantitative real-time PCr was performed in an aBI 
PrISM 7500 system (applied Biosystems). TaqMan minor 
groove binder probes (applied Biosystems, assay-by-
Design) were obtained for amplification of the following 
genes: runt-related transcription factor 2 (runx2), osterix 
(osx) and alP using Premix ex-Taq polymerase (Takara 
Bio Inc., otsu, Japan). The messenger rNa (mrNa) copy 
numbers were calculated for each sample using the cycle 
threshold value and normalized against 18S ribosomal 
rNa, as previously reported.44,45 results were expressed as 
n-fold mrNa values versus corresponding values in non-
treated control cells.
Statistical analysis. results are expressed as mean ± stan-
dard error of the mean (sem) throughout the text. Differences 
among groups were analyzed by the Kruskal-Wallis test fol-
lowed by Dunn’s post hoc test and p < 0.05 was considered 
significant. Statistical analysis was performed with SPSS v21 
software (IBM Corp., armonk, New york).
Results
Both n- and C-terminal PTHrP peptides counteract H2O2-
induced oxidative stress in osteoblastic cells. First, we 
aimed to explore whether N- and C-terminal PTHrP pep-
tides might be able to prevent roS production by the 
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H2O2
Parathyroid hormone (PTH) and both N- and C-terminal PTH-related protein (PTHrP) peptides prevented the increase in malondialdehyde (MDa) levels 
and caspase-3 activation induced by H2o2 in osteoblastic cells. Cells were pretreated with the different peptides at 100 nM followed by H2o2 (200 μM) for 
a) and b) ten minutes, or c) two to 24 hours. Changes in MDa levels in a) MC3T3-E1 cells and b) human osteoblastic cells, and in c) caspase-3 activity in 
MC3T3-E1 cells, are shown. Data are mean ± standard error of the mean (sem) of three independent experiments performed at least in triplicate. *p < 0.05 
versus corresponding time control; †p < 0.01 versus corresponding time control; ‡p < 0.05 versus H2o2 at the corresponding time; §p < 0.01 versus H2o2 at 
the corresponding time. Kruskal–Wallis test followed by Dunn’s post hoc test. N-ter(1-37), C-ter(107-139), and ost denote PTHrP (1-37), PTHrP (107-139), 
and osteostatin, respectively.
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prominent oxidative stress-related agent H2o2 in osteo-
blastic cells. Short exposure (ten minutes) of MC3T3-E1 
cells to 200 µM H2o2 produced a significant (p < 0.01) 
increase in intracellular roS (Figs 1 and 2). However, 
this increase was prevented by each N- or C-terminal 
PTHrP peptide tested or PTH (1-34) (a positive control) 
(each at 100 nM). Further confirmation of the capacity of 
these peptides to impair oxidative stress was obtained by 
using confocal microscopy to assess H2o2-induced DCF 
fluorescence changes in MC3T3-E1 cells and in hoBs 
(Figs 3 and 4).
It has been demonstrated that increased cell roS lead to 
an augmented FoXo transcriptional activity.46,47 Thus, we 
next examined the changes in this activity elicited by H2o2 
and the possible modulatory effects of the different peptides 
evaluated in MC3T3-E1 cells. We found that pre incubation 
with either PTHrP peptide or PTH (1-34) abrogated the oxi-
dant-related effect of H2o2 in these cells (Fig. 5).
oxidative stress induces different kinds of cellular 
damage, which impairs regular cell function.1 Thus, we 
next analyzed the changes in MDa levels induced by 
H2o2 as an oxidative stress damage marker and the pos-
sible modulatory action of the different PTHrP peptides. 
as expected, this oxidative agent increased MDa levels, 
which were normalized by pretreating MC3T3-E1 cells 
and hoBS with the PTHrP peptides or PTH (1-34) (Figs 6a 
and b). It has been demonstrated that oxidative stress 
triggers an apoptotic cascade resulting in caspase activa-
tion.21 We found that caspase-3 activity increased signifi-
cantly after 24 hours of exposure to H2o2, and all of the 
peptides tested were similarly effective in normalizing 
this activity in these cells (Fig. 6c).
Protective effects of both n- and C-terminal PTHrP pep-
tides against the deleterious effects of H2O2 on osteoblastic 
cell function. osteoblast growth has been shown to be 
altered negatively by oxidative stress.18,19 This prompted 
us to examine whether PTHrP would prevent the nega-
tive effects of a short exposure (one hour) to H2o2 during 
MC3T3-E1 cell growth for five days. Indeed, we showed a 
diminished cell proliferation with H2o2 treatment, which 
was similarly compensated for by both N- and C-terminal 
PTHrP peptides (Fig. 7a). of note, CaT (used as an anti-
oxidant control) produced a dramatic stimulation for 
cell proliferation, suggesting that basal H2o2 levels keep 
proliferation under control in these cells. In addition, 
we found that either the N- or C-terminal PTHrP domain 
could counteract the inhibitory effect of acute exposure 
of MC3T3-E1 cells to H2o2 in the presence or absence of 
FBS on cell viability (Fig. 7b).
We also aimed to explore the putative changes elic-
ited by short exposure to H2o2 on various osteoblast dif-
ferentiation markers and the modulatory effect of PTHrP 
peptides in MC3T3-E1 cells and hoBs. This oxidant was 
found to reduce alP activity in both osteoblastic cell 
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Parathyroid hormone (PTH) and both N- and C-terminal PTH-related protein (PTHrP) peptides counteract the deleterious effects of H2o2 on MC3T3-E1 cell 
growth. Cells were preincubated with different inhibitors for 30 minutes: rp-cyclic 3’,5’-hydrogen phosphorothioate adenosine triethylammonium salt 
(rp-caMPS; 25 µM), protein phosphatase 1 and Su1498 (5 µM) or calphostin C (CalpC) (250 nM), and then treated with PTHrP peptides (100 nM) before 
exposure to H2o2. Control cells were not treated. a) For calculation of cell proliferation, cell growth percentage values in treated samples were expressed 
as n-fold versus control (normalized to 1). Catalase (200 u/ml) was used as an antioxidant control. b) Cell viability was expressed as the percentage of 
viable cells over total cells. Data are mean ± standard error of the mean (sem) of three independent experiments performed at least in triplicate. *p < 0.05 
versus control; †p < 0.01 versus control; ‡p < 0.05 versus H2o2; §p < 0.01 versus H2o2; probability associated with comparison a (ap) < 0.05 versus H2o2 
+ N-ter (1-37); probability associated with comparison B (Bp) < 0.05 versus H2o2 + ost. Kruskal–Wallis test followed by Dunn’s post hoc test. N-ter(1-37), 
C-ter(107-139) and ost denote PTHrP (1-37), PTHrP (107-139), and osteostatin, respectively. FBS, fetal bovine serum.
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types (Figs 8a and b), as well as the gene expression of 
alP, runx2, and osx in MC3T3-E1 cells (Fig. 8c); these 
deleterious effects were prevented by pretreating these 
cells with each PTHrP peptide tested (Figs 8a to c).
as a specificity control of each PTHrP peptide action in 
this setting, we used several inhibitors or antagonists. 
Thus, we found that rp-caMPS (a PKa inhibitor) inhibited 
the ability of PTHrP (1-37) to preserve cell viability and 
alP activity upon exposure to H2o2 in MC3T3-E1 cells, 
whereas CalpC (a PKC inhibitor), protein phosphatase 1 
(Src activation inhibitor) or Su1498 (vEGFr2 activation 
inhibitor) abrogated such ability of osteostatin to restore 
alP activity upon oxidant treatment in these cells (Figs 
7b, 8a, and 8b). In addition, PTHrP (7-34) (a PTHr1 
antagonist) and anti-osteostatin antiserum C7 inhibited 
the positive effects of PTHrP (1-37) and osteostatin, 
respectively, on osteoblast differentiation-related genes 
in these cells following H2o2 treatment (Fig. 8c).
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Parathyroid hormone (PTH) and both N- and C-terminal PTH-related protein (PTHrP) peptides counteract the negative effects of H2o2 on osteoblastic cell 
differentiation. a) MC3T3-E1 cells and b) human osteoblastic cells were preincubated or not with different inhibitors, as described in the legend for Figure 7, 
and then treated or not (control) with the PTHrP peptides (100 nM) before exposure to H2o2. alkaline phosphatase (alP) activity was expressed as n-fold over 
control (mean ± standard error of the mean (sem): 2.6 nmoles/min/mg (sem 0.5) and 4.3 nmoles/min/mg (sem 0.22) protein for MC3T3-E1 cells and human 
osteoblastic cells, respectively). c) MC3T3-E1 cells were pre treated with the PTHrP peptides in the presence or absence of the antagonist PTHrP (7-34) or the 
anti-osteostatin antiserum C7 before addition of H2o2. Changes in gene expression of alP, runt-related transcription factor 2 (runx2) and osterix (osx) were 
analyzed in cell total rNa isolates by quantitative polymerase chain reaction. †p < 0.01 versus control; ‡p < 0.05 versus H2o2;§p < 0.01 versus H2o2; probabil-
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PTHrP (107-139) and osteostatin, respectively. rp-caMPS, rp-cyclic 3’,5’-hydrogen phosphorothioate adenosine triethylammonium salt; CalpC, calphostin C; 
mrNa, messenger rNa.
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Discussion
oestrogen depletion has traditionally been considered 
the hallmark of the pathogenesis of involutional osteo-
porosis,48 but age-related factors intrinsic to bone, 
mainly oxidative stress, appear also to contribute to 
bone loss in this condition.1,2 In this regard, the recent 
finding that intermittent PTH, currently the only bone 
anabolic therapy, may function, as least partially, 
through reducing oxidative stress in aged bone26 pro-
vides insight into the mechanisms and possible treat-
ment options for bone loss. However, the use of 
antioxidants alone or in combination with PTH presents 
several drawbacks. Thus, common antioxidants such as 
N-acetyl cysteine and CaT produce a decrease in roS lev-
els, but can also decrease osteoblastogenesis by blocking 
Wnt pathway activation,49 thereby inhibiting β-catenin-
dependent transcription of osteogenic genes.26 In addi-
tion, antioxidants have anti-osteoclastic features that 
would inhibit bone remodelling.26
Previous studies have shown the ability of N- and 
C-terminal PTHrP peptides to promote cell growth and 
osteoblast differentiation in MC3T3-E1 cells and other 
osteoblastic cell preparations. Studies on these proteins 
have also reported their osteogenic properties in vivo in 
high oxidative stress-related conditions, namely diabetes 
mellitus and ovariectomized mice.24,25,27-29,32,34-36,39 very 
recently, the osteoregenerative features of both PTHrP 
(1-37) and osteostatin have been reported in vivo in an 
ageing rat model with diabetes mellitus, although only 
indirect evidence for the antioxidant capacities of these 
peptides was provided.50
In this in vitro study, we disclose the antioxidant capac-
ity of both N- and C-terminal domains of PTHrP in well-
characterized osteoblastic cells. To induce oxidative stress, 
we used H2o2 at concentrations widely used in previous 
studies.18,38,51 roS elevation can impair bone formation 
by interaction with the Wnt/β-catenin pathway.17 Thus, 
roS-mediated activation of FoXo transcription factors 
diverts β-catenin from the promoter regions of genes 
involved in proliferation and differentiation of cells of the 
osteoblastic lineage, impairing these cellular pro-
grammes.52 our data show that these PTHrP peptides 
were able to prevent the H2o2-induced generation of cell 
roS in both murine osteoblastic cells and hoBs, and 
accordingly, the increase in FoXo transcriptional activity 
as demonstrated by a FoXo-luc reporter assay in the for-
mer cells. This is consistent with recent results showing 
the ability of PTHrP to increase Wnt/β-catenin signalling in 
osteoblastic cells exposed to high glucose concentrations, 
another oxidative stress-related scenario.33 oxidative 
stress also triggers cellular damage and apoptosis through 
caspase activation.21,53 Here we show that pretreatment 
with these peptides decreased lipid peroxidation and 
blocked caspase-3 activation, thus protecting MC3T3-E1 
cells from apoptosis in both osteoblastic cell types used.
It has been reported previously that oxidative stress 
impairs osteoblast function.5,17-19,21,51 In the present 
study, we report that short exposure (one to six hours) of 
MC3T3-E1 cells to H2o2 significantly decreased cell prolif-
eration and viability by approximately 30%. This decrease 
is moderate compared with previous data in the same 
osteoblast cell line, although previous studies used pro-
longed exposure to the oxidant in a FBS-containing 
medium and/or higher oxidant concentration than that 
used herein.18,19 In addition, alP enzymatic activity and 
mrNa levels, as well as gene expression of other well-
known osteoblast differentiation markers, were all dimin-
ished by acute exposure to H2o2, and this was also 
prevented by pretreatment with both PTHrP peptides in 
MC3T3-E1 cells and hoBs.
Previous reports have shown the important role of the 
caMP/PKa pathway in the anabolic actions elicited by 
the homologous N-terminal domains of PTH and 
PTHrP.22,24,25,35,36 This fact was confirmed by using a PKa 
inhibitor in the present oxidative stress scenario. In addi-
tion, specific inhibitors of PKC and Src-dependent 
vEGFr2 activation inhibited the protective/restoring role 
of osteostatin in viability and alP activity, supporting the 
notion that both pathways play a major role in its osteo-
genic actions.24,25,36 our results thus further emphasize 
the involvement of distinct signalling pathways trig-
gered by both the N- and C-terminal PTHrP domains in 
osteoblasts.
Taken together, the present data indicate that both N- 
and C-terminal domains of PTHrP display various anti-
oxidant features in both murine osteoblastic cells and 
hoBs. However, we understand that this is an in vitro 
study and caution should be taken when translating our 
results to an in vivo scenario. Even so, these findings pro-
vide novel insights that add support to the generally 
accepted use of PTHrP peptides as osteoporosis therapy.
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